Management of Endoscopy in Patients with Elevated INR
For patients with elevated INR requiring endoscopy, the approach depends critically on whether the procedure is low-risk or high-risk and the patient's thrombotic risk: for low-risk procedures, continue warfarin if INR is within therapeutic range or reduce dose if INR is 3.5-5.0; for high-risk procedures, stop warfarin 5 days before and ensure INR <1.5 prior to the procedure. 1
Risk Stratification Framework
Procedure Risk Classification
High-risk procedures include 1:
- Polypectomy
- ERCP with sphincterotomy
- Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)
- Stricture dilation
- Variceal therapy
- PEG placement
- EUS with sampling or intervention
Low-risk procedures include 1:
- Diagnostic endoscopy with biopsies
- Biliary/pancreatic stenting
- Luminal stenting
- EUS without sampling
Management Algorithm by Procedure Risk
For Low-Risk Procedures
Continue warfarin and follow this protocol 1:
- Check INR during the week before endoscopy
- If INR is within therapeutic range (2.0-3.0): Proceed with usual daily dose
- If INR is above therapeutic range but <5.0: Reduce daily warfarin dose until INR returns to therapeutic range, then proceed
- If INR ≥5.0: Defer the endoscopy and contact anticoagulation clinic or medical practitioner for advice
For High-Risk Procedures
The approach differs based on thrombotic risk:
Low Thrombotic Risk Patients 1:
- Stop warfarin 5 days before the procedure
- Check INR immediately prior to procedure to ensure <1.5 (this is the critical target)
- Restart warfarin the evening of the procedure with usual daily dose
- Check INR 1 week later to ensure adequate anticoagulation
High Thrombotic Risk Patients 1:
High-risk conditions include prosthetic metal heart valve, AF with mitral stenosis, AF with previous stroke/TIA within 3 months, or previous VTE on anticoagulation.
- Stop warfarin 5 days before the procedure
- Two days after stopping warfarin, commence therapeutic dose LMWH
- Give last LMWH dose at least 24 hours prior to procedure
- Check INR prior to procedure to ensure <1.5
- Resume warfarin evening of procedure with usual dose
- Restart therapeutic LMWH the day after procedure
- Continue LMWH until satisfactory INR achieved
Critical Target INR
The target INR for high-risk procedures is <1.5 1. This is a strong recommendation based on high-quality evidence for low thrombotic risk patients and moderate-quality evidence for high thrombotic risk patients.
Important Clinical Considerations
Reversal Agents: Use with Caution
Research evidence suggests that reversal agent use is actually associated with increased thromboembolism risk rather than decreased rebleeding 2. In one study, patients managed without reversal agents, heparin bridging, or anticoagulant interruption had only one rebleeding event and no thromboembolic events. This creates a clinical dilemma that must be balanced against guideline recommendations.
The INR Paradox in Acute GI Bleeding
Interestingly, research shows that higher INR levels (particularly >7.5) are associated with LOWER likelihood of finding an endoscopically significant bleeding source 3. At INR >7.5, the likelihood of finding a significant lesion falls to <20%. This suggests that very elevated INR may cause more diffuse mucosal bleeding rather than discrete lesions requiring intervention.
Timing Considerations
For patients requiring endoscopy within 12 hours of presentation, there is a 3.7-fold increased likelihood of identifying a bleeding source 3. This supports early endoscopy in acute settings, even with elevated INR.
Common Pitfalls to Avoid
Don't automatically reverse all elevated INRs: The guidelines distinguish between slightly elevated INR (which may only require dose adjustment) and significantly elevated INR (≥5.0, which requires deferral)
Don't forget to check pre-procedure INR: Even after stopping warfarin for 5 days, always verify INR <1.5 before high-risk procedures
Don't use heparin bridging indiscriminately: Reserve LMWH bridging only for high thrombotic risk patients, as it adds complexity and potential bleeding risk
Don't delay restarting anticoagulation: Resume warfarin the evening of the procedure to minimize thrombotic risk
The key principle is balancing hemorrhagic and thrombotic risks through a structured, risk-stratified approach rather than blanket reversal of all elevated INRs.